Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines

Tieu, Joanna; Smith, Rona; Basu, Neil; Brogan, Paul; D�Cruz, David; Dhaun, Neeraj; Flossmann, Oliver; Harper, Lorraine; Jones, Rachel B; Lanyon, Peter C; Luqmani, Raashid A; McAdoo, Stephen P; Mukhtyar, Chetan; Pearce, Fiona A; Pusey, Charles D; Robson, Joanna C; Salama, Alan D; Smyth, Lucy; Watts, Richard A; Willcocks, Lisa C; Jayne, David R W

doi:10.1093/rheumatology/kez640

All Outputs (4)

BSR guideline on the management of adults with systemic lupus erythematosus (SLE) 2018: Baseline multi-centre audit in the UK (2020)
Journal Article
Pearce, F. A., Rutter, M., Sandhu, R., Batten, R. L., Garner, R., Little, J., …Lanyon, P. C. (2021). BSR guideline on the management of adults with systemic lupus erythematosus (SLE) 2018: Baseline multi-centre audit in the UK. Rheumatology, 60(3), 1480-1490. https://doi.org/10.1093/rheumatology/keaa759

Objectives: To assess the baseline care provided to patients with SLE attending UK Rheumatology units, audited against standards derived from the recently published BSR guideline for the management of adults with SLE, the NICE technology appraisal fo... Read More about BSR guideline on the management of adults with systemic lupus erythematosus (SLE) 2018: Baseline multi-centre audit in the UK.

Risk of death among people with rare autoimmune diseases compared with the general population in England during the 2020 COVID-19 pandemic (2020)
Journal Article
Peach, E., Rutter, M., Lanyon, P., Grainge, M. J., Hubbard, R., Aston, J., …Pearce, F. (2021). Risk of death among people with rare autoimmune diseases compared with the general population in England during the 2020 COVID-19 pandemic. Rheumatology, 60(4), 1902–1909. https://doi.org/10.1093/rheumatology/keaa855

Objectives: To quantify the risk of death among people with rare autoimmune rheumatic diseases (RAIRD) during the UK 2020 COVID-19 pandemic compared with the general population, and compared with their pre-COVID risk. Methods: We conducted a cohort s... Read More about Risk of death among people with rare autoimmune diseases compared with the general population in England during the 2020 COVID-19 pandemic.

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis (2020)
Journal Article
Smith, R. M., Jones, R. B., Specks, U., Bond, S., Nodale, M., Aljayyousi, R., …Jayne, D. (2020). Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 79(9), 1243-1249. https://doi.org/10.1136/annrheumdis-2019-216863

Objectives: Evaluation of rituximab and glucocorticoids as therapy to induce remission after relapse in ANCA-associated vasculitis (AAV) in a prospective observational cohort of patients enrolled into the induction phase of the RITAZAREM trial.

Me... Read More about Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis.

Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines (2020)
Journal Article
Tieu, J., Smith, R., Basu, N., Brogan, P., D’Cruz, D., Dhaun, N., …Jayne, D. R. W. (2020). Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines. Rheumatology, 59(4), e24-e32. https://doi.org/10.1093/rheumatology/kez640